Yegor Vassetzky

Dr. Yegor Vassetzky

CNRS UMR9018, Institut Gustave Roussy, Villejuif, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in Cell
Verified
Journal Article
Closed access
Jean-marc LemaitreJean-marc Lemaitre
Jean-marc Lemaitre
EDEtienne Danis
Etienne Danis
PPPhilippe Pasero
Philippe Pasero
Yegor VassetzkyYegor Vassetzky
Yegor Vassetzky
MMMarcel Méchali
Marcel Méchali

1 August 2019 in Trends in Cell Biology
Verified
Journal Article
Closed access
OIOlga V. Iarovaia
Olga V. Iarovaia
EMElizaveta P. Minina
Elizaveta P. Minina
ESEugene V. Sheval
Eugene V. Sheval
DODaria Onichtchouk
Daria Onichtchouk
Svetlana DokudovskayaSvetlana Dokudovskaya
Svetlana Dokudovskaya
Yegor VassetzkyYegor Vassetzky
Yegor Vassetzky

1 September 2012 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
ATAhmed Turki
Ahmed Turki
MHMaurice Hayot
Maurice Hayot
GCGilles Carnac
Gilles Carnac
FPFabien Pillard
Fabien Pillard
EPEmilie Passerieux
Emilie Passerieux
DLDalila Laoudj-Chenivesse
Dalila Laoudj-Chenivesse

1 January 2010 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MBMarietta Barro
Marietta Barro
GCGilles Carnac
Gilles Carnac
SFSébastien Flavier
Sébastien Flavier
JMJacques Mercier
Jacques Mercier
Yegor VassetzkyYegor Vassetzky
Yegor Vassetzky
DLDalila Laoudj‐Chenivesse
Dalila Laoudj‐Chenivesse
Facioscapulohumeral dystrophy (FSHD) is a muscular hereditary disease with a prevalence of 1 in 20,000 caused by a partial deletion of a subtelomeric repeat array on chromosome 4q. However, very little is known about the pathogenesis as well as the molecular and biochemical changes linked to the progressive muscle degeneration observed in these patients. Several studies have investigated possible pathophysiological pathways in FSHD myoblasts and mature muscle cells but some of these reports were apparently in contradiction. The discrepancy between these studies may be explained by differences between the sources of myoblasts. Therefore, we decided to thoroughly analyze affected and unaffected muscles from patients with FSHD in terms of vulnerability to oxidative stress, differentiation capacity and morphological abnormalities. We have established a panel of primary myoblast cell cultures from patients affected with FSHD and matched healthy individuals. Our results show that primary myoblasts are more susceptible to an induced oxidative stress than control myoblasts. Moreover, we demonstrate that both types of FSHD primary myoblasts differentiate into multi‐nucleated myotubes, which present morphological abnormalities. Whereas control myoblasts fuse to form branched myotubes with aligned nuclei, FSHD myoblasts fuse to form either thin and branched myotubes with aligned nuclei or large myotubes with random nuclei distribution. In conclusion, we postulate that these abnormalities could be responsible for muscle weakness in patients with FSHD and provide an important marker for FSHD myoblasts.

1 September 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
YMYinxing Ma
Yinxing Ma
Yegor VassetzkyYegor Vassetzky
Yegor Vassetzky
Svetlana DokudovskayaSvetlana Dokudovskaya
Svetlana Dokudovskaya

17 November 2004 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
DLDalila Laoudj-Chenivesse
Dalila Laoudj-Chenivesse
GCGilles Carnac
Gilles Carnac
Bisbal CatherineBisbal Catherine
Bisbal Catherine
GHGerald Hugon
Gerald Hugon
SBSandrine Bouillot
Sandrine Bouillot
AFAnne Fernandez
Anne Fernandez